What have we really learned from 'LIBERATE' trial?

被引：0
作者：
Dimitrakakis, Constantine [1 ,2 ]
Tsigginou, Alexandra [1 ]
Keramopoulos, Dimitris [1 ]
Antsaklis, Aris [1 ]
机构：
[1] Univ Athens, Sch Med, Dept Ob Gyn 1, Athens 11528, Greece
[2] NICHD, NIH, Bethesda, MD USA
来源：
MATURITAS | 2010年 / 66卷 / 01期
关键词：
Breast cancer; Tibolone; Recurrence; LIBERATE trial; Menopausal symptoms; BREAST-CANCER; POSTMENOPAUSAL WOMEN; VASOMOTOR SYMPTOMS; DOUBLE-BLIND; TIBOLONE; RECURRENCE; SURVIVAL; THERAPY;
D O I：
10.1016/j.maturitas.2010.02.012
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
LIBERATE trial reports that Tibolone use increases the risk of recurrence in breast cancer patients with vasomotor symptoms. However, there are some uncertainties and weak points in the study. Emerged questions are if interpretation of the results could be extrapolated to all breast cancer patients or there are specific subgroups that could use Tibolone without increasing relapse rate. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：99 / 100
页数：2
相关论文
共 6 条
  • [1] The effects of tibolone in older postmenopausal women
    Cummings, Steven R.
    Ettinger, Bruce
    Delmas, Pierre D.
    Kenemans, Peter
    Stathopoulos, Victoria
    Verweij, Pierre
    Mol-Arts, Mirjam
    Kloosterboer, Lenus
    Mosca, Lori
    Christiansen, Claus
    Bilezikian, John
    Kerzberg, Eduardo Mario
    Johnson, Susan
    Zanchetta, Jose
    Grobbee, Diederich E.
    Seifert, Wilfried
    Eastell, Richard
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (07) : 697 - 708
  • [2] Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer
    Dimitrakakis, C
    Keramopoulos, D
    Vourli, G
    Gaki, V
    Bredakis, N
    Keramopoulos, A
    [J]. CLIMACTERIC, 2005, 8 (04) : 342 - 351
  • [3] Early Breast Cancer Trialists' Collaborative Group (EBCTCG), 2005, LANCET, V365, P1687, DOI [10.1016/S0140-6736(05)66544-0, DOI 10.1016/S0140-6736(05)66544-0]
  • [4] Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial
    Kenemans, Peter
    Bundred, Nigel J.
    Foidart, Jean-Michel
    Kubista, Ernst
    von Schoultz, Bo
    Sismondi, Piero
    Vassilopoulou-Sellin, Rena
    Yip, Cheng Har
    Egberts, Jon
    Mol-Arts, Mirjam
    Mulder, Roel
    van Os, Steve
    Beckmann, Matthias W.
    [J]. LANCET ONCOLOGY, 2009, 10 (02) : 135 - 146
  • [5] Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer
    Rock, Cheryl L.
    Flatt, Shirley W.
    Laughlin, Gail A.
    Gold, Ellen B.
    Thomson, Cynthia A.
    Natarajan, Loki
    Jones, Lovell A.
    Caan, Bette J.
    Stefanick, Marcia L.
    Hajek, Richard A.
    Al-Delaimyl, Wael K.
    Stanczyk, Frank Z.
    Pierce, John P.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2008, 17 (03) : 614 - 620
  • [6] Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study
    Swanson, Stephen G.
    Drosman, Steven
    Helmond, Frans A.
    Stathopoulos, Victoria M.
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2006, 13 (06): : 917 - 925
1